Literature DB >> 20889192

Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging.

Rajiv K Pruthi1, Todd M Daniels, John A Heit, Dong Chen, Whyte G Owen, William L Nichols.   

Abstract

INTRODUCTION: Electrophoretic analysis of plasma von Willebrand factor (VWF) multimer distribution and infrastructure is essential for subtyping von Willebrand disease. To improve the sensitivity, precision and efficiency of this assay, we developed and validated a new in-gel infrared fluorescent VWF multimer imaging method to visualize and quantify VWF multimers directly in the agarose gel, thus eliminating electroblotting or autoradiographic steps. MATERIALS/
METHODS: VWF multimer analyses of plasma samples from 34 patients with known von Willebrand disease or acquired von Willebrand syndrome, 9 patients with acquired VWF abnormalities, 26 normal volunteer donors and 49 patient samples referred for von Willebrand factor multimer analysis were performed by both traditional autoradiographic and the new infra-red imaging methods and compared. VWF multimer image data were electronically acquired, archived and analyzed.
RESULTS: The in-gel infrared method has a sensitivity of detecting VWF antigen as low as approximately 1.6 IU/dL, a reliable fluorescent intensity with intra- and inter-day variability (CV) of 5% and 6% respectively, and provides superior imaging resolution and shortened test turnaround time. Using intermediate resolution agarose gel electrophoresis, the infra-red method sensitively detects subtle loss of highest molecular weight von Willebrand factor multimers in plasmas with acquired VWF abnormalities and in commercial normal reference plasmas, and provides evidence of increased proteolysis of ultralarge multimers in some type 2 VWD plasmas.
CONCLUSIONS: The in-gel infrared fluorescent VWF multimer imaging method provides a sensitive, reliable, efficient and robust system to improve laboratory testing for von Willebrand disease classification.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889192     DOI: 10.1016/j.thromres.2010.09.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding.

Authors:  Rajiv K Pruthi
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

2.  Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy.

Authors:  Joseph L Blackshear; Hartzell V Schaff; Steve R Ommen; Dong Chen; William L Nichols
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

3.  Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study).

Authors:  Joseph L Blackshear; Ewa M Wysokinska; Robert E Safford; Colleen S Thomas; Mark E Stark; Brian P Shapiro; Steven Ung; Gretchen S Johns; Dong Chen
Journal:  Am J Cardiol       Date:  2012-11-17       Impact factor: 2.778

4.  Platelet recruitment to venous stent thrombi.

Authors:  Robert D McBane; Krzysztof Karnicki; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

5.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

6.  Benchtop von Willebrand Factor Testing: Comparison of Commercially Available Ventricular Assist Devices and Evaluation of Variables for a Standardized Test Method.

Authors:  Phillip A Coghill; Suren Kanchi; Zheila J Azartash-Namin; James W Long; Trevor A Snyder
Journal:  ASAIO J       Date:  2019-07       Impact factor: 2.872

7.  Evidence for the Misfolding of the A1 Domain within Multimeric von Willebrand Factor in Type 2 von Willebrand Disease.

Authors:  Alexander Tischer; Maria A Brehm; Venkata R Machha; Laurie Moon-Tasson; Linda M Benson; Katelynn J Nelton; Rachel R Leger; Tobias Obser; Marina Martinez-Vargas; Steven T Whitten; Dong Chen; Rajiv K Pruthi; H Robert Bergen; Miguel A Cruz; Reinhard Schneppenheim; Matthew Auton
Journal:  J Mol Biol       Date:  2019-10-17       Impact factor: 5.469

Review 8.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

9.  Severe dengue is associated with consumption of von Willebrand factor and its cleaving enzyme ADAMTS-13.

Authors:  Kis Djamiatun; Andre J A M van der Ven; Philip G de Groot; Sultana M H Faradz; D Hapsari; Wil M V Dolmans; Silvie Sebastian; Rob Fijnheer; Quirijn de Mast
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

10.  Platelet activation risk index as a prognostic thrombosis indicator.

Authors:  K E Zlobina; G Th Guria
Journal:  Sci Rep       Date:  2016-07-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.